Drugs for Prostate Disease (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):
(show all 44)
# |
|
Name |
Status |
Phase |
Clinical Trials |
Cas Number |
PubChem Id |
1 |
|
Povidone-iodine |
Approved |
Phase 4 |
|
25655-41-8 |
|
Synonyms:
Iodopovidone
Povidone iodine
Povidone, iodinated
|
|
|
2 |
|
Iodine |
Approved, Investigational |
Phase 4 |
|
7553-56-2 |
807 |
Synonyms:
Cadex
Diiodine
I2
Iode
Iodine
Iodine 127
Iodine-127
Iodine-molecule
|
Iodio
iodo
Iodum
Jod
Jood
Molecular iodine
NSC-42355
Tincture iodine
|
|
3 |
|
Povidone K30 |
Approved, Experimental, Withdrawn |
Phase 4 |
|
9003-39-8 |
6917 131751496 |
Synonyms:
1-Ethenyl-2-pyrrolidinone
1-Ethenyl-2-pyrrolidinone (9ci)
1-Ethenyl-2-pyrrolidinone homopolymer
1-Ethenyl-2-pyrrolidinone homopolymer, 9ci
1-Ethenyl-2-pyrrolidinone polymers
1-Ethenyl-2-pyrrolidinone, homopolymer
1-Vinyl-2-pyrrolidinone
1-Vinyl-2-pyrrolidinone cross-linked insoluble polymer
1-Vinyl-2-pyrrolidinone homopolymer
1-Vinyl-2-pyrrolidinone polymer
1-Vinyl-2-pyrrolidinone, monomer
1-Vinyl-2-pyrrolidinone, polymer
1-Vinyl-2-pyrrolidone
1-Vinyl-2-pyrrolidone polymer
1-Vinylpyrrolidin-2-one
1-vinylpyrrolidin-2-one homopolymer
1-Vinylpyrrolidinone
1-Vinylpyrrolidone
2-Pyrrolidinone, 1-ethenyl, homopolymer
2-Pyrrolidinone, 1-ethenyl-, homopolymer
2-Pyrrolidinone, 1-vinyl-, polymers
Agent at 717
Agent at-717
Agrimer
Albigen a
Aldacol Q
Alphadine
Alphadines
Antaron P 804
Arufil
Betadine
Betadines
Betaisodona
Betaisodonas
Bolinan
Bolinan 40
Crospovidone
Disadine
Disadines
Dulcilarme
Dulcilarmes
Duratears free
Enterode
Enterodes
Enterodez
Ganex P 804
Ganex P-804
Hemodesis
Hemodez
Huntington laboratories brand OF povidone iodine
Huntington laboratories brand OF povidone-iodine
Hypotear
Hypotears
Isodine
Isodines
K 115 (Polyamide)
K 25
K 25 (Polymer)
K 30
K 30 (Polymer)
K 60
K 60 (Polymer)
K115 (Polyamide)
K25 (Polymer)
K30 (Polymer)
K60 (Polymer)
Kollidin CLM
Kollidon
Kollidon 17
Kollidon 25
'Kollidon 25'
Kollidon 30
Kollidon CL
Lacophtal
Lacri-stulln
Lagrifilm
Liquifilm lagrimas
Luviskol
Luviskol K 30
Luviskol K 90
Luviskol K30
Luviskol K-30
Luviskol K90
N- Vinyl pyrrolidone
Neocompensan
Nutrivisc
N-Vinyl pyrrolidone
N-Vinyl-2-pyrrolidinone
N-Vinyl-2-pyrrolidone
N-Vinyl-2-pyrrolidone polymer
N-Vinylbutyrolactam polymer
N-Vinylpyrrolidinone
N-Vinylpyrrolidinone polymer
N-Vinylpyrrolidone
N-Vinylpyrrolidone polymer
N-Vinylpyrrolidone-2
Oculotect
Peragal ST
Peregal ST
Periston
Periston-N
Peviston
Pharmadine
Pharmadines
'plasdone'
Plasdone
Plasdone 4
Plasdone K 29-32
Plasdone K-26/28
Plasdone K29/32
Plasdone K29-32
|
Plasdone no. 4
Plasdone XL
Plasmosan
Polividone
Polvidone
Poly(1-(2-oxo-1-pyrrolidinyl)-1,2-ethanediyl)
Poly(1-(2-oxo-1-pyrrolidinyl)ethylene)
Poly(1-ethenyl-2-pyrrolidinone)
Poly(1-vinyl-2-pyrrolidinone)
Poly(1-vinyl-2-pyrrolidinone) homopolymer
Poly(1-vinyl-2-pyrrolidinone) hueper's polymer no.1
Poly(1-vinyl-2-pyrrolidinone) hueper's polymer no.2
Poly(1-vinyl-2-pyrrolidinone) hueper's polymer no.3
Poly(1-vinyl-2-pyrrolidinone) hueper's polymer no.4
Poly(1-vinyl-2-pyrrolidinone) hueper's polymer no.5
Poly(1-vinyl-2-pyrrolidinone) hueper's polymer no.6
Poly(1-vinyl-2-pyrrolidinone) hueper's polymer no.7
Poly(1-vinyl-2-pyrrolidone)
Poly(1-vinylpyrrolidinone)
Poly(N-vinyl-2-pyrrolidinone)
Poly(N-vinyl-2-pyrrolidone)
Poly(N-vinylbutyrolactam)
Poly(N-vinylpyrrolidinone)
Poly(N-vinylpyrrolidone)
Poly(vinylpolypyrrolidone)
Poly(vinylpyrrolidinone)
Poly(vinylpyrrolidone)
Polyclar a. t
Polyclar a. t.
Polyclar at
Polyclar H
Polyclar L
Polyclar-at
Polygyl
Poly-N-vinyl pyrrolidone
Poly-N-vinylpyrrolidone
Polyplasdone
Polyplasdone XL
Polyvidon
Polyvidons
Polyvidonum
Polyvinyl pyrrolidone
Polyvinylpolypyrrolidone
Polyvinylpyrrolidone
Polyvinylpyrrolidone iodine
Polyvinylpyrrolidone iodines
Polyvinylpyrrolidone K 30
Polyvinylpyrrolidone K-29/32
Polyvinylpyrrolidone K30
Polyvinylpyrrolidone polymers
Polyvinylpyrrolidone, cross-linked
Povidona
Povidone
Povidone iodine
Povidone K29/32
Povidone K29-32
Povidone(usan)
Povidone, ban, usan
Povidone, unspecified
Povidone-iodine
Povidone-iodines
Povidonum
Protagen
Protagens
Protagent
Providine
Providines
PVP 1
PVP 2
PVP 3
PVP 4
PVP 40
PVP 5
PVP 6
PVP 7
PVP Iodine
PVP K 3
PVP K30
PVP K-30
PVP10_SIAL
PVP40_SIAL
PVP-I
PVP-Iodine
PVP-Iodines
PVP-K 15
PVP-K 3
PVP-K 30
PVP-K 60
PVP-K 90
PVPP
Refresh
Sauflon
Soothe
Subtosan
Tears plus
Tolpovidone I 131
Tolpovidone I-131
Toxobin
Unifluid
Unspecified povidone
Vidirakt S mit PVP
Vidisic PVP ophtiole
Vinisil
Vinyl-2-pyrrolidone
Vinylbutyrolactam
Vinylpyrrolidinone
Vinylpyrrolidinone polymer
Vinylpyrrolidone
Vinylpyrrolidone polymer
V-Pyrol
Wet-comod
|
|
4 |
|
Alfuzosin |
Approved, Investigational |
Phase 4 |
|
81403-80-7 |
2092 |
Synonyms:
(±)-N-[3-[(4-AMINO-6,7-DIMETHOXY-2-QUINAZOLINYL)METHYLAMINO]PROPYL]TETRAHYDRO-2-FURAMIDE
Alfetim
Alfusosine
Alfusozine
ALFUZOSIN
Alfuzosin hydrochloride
Alfuzosina
Alfuzosine
Alfuzosinum
Alphuzosine
|
Benestan
N-(3-((4-Amino-6,7-dimethoxy-2-quinazolinyl)methylamino)propyl)tetrahydro-2-furancarboxamide
N-[3-[(4-AMINO-6,7-DIMETHOXY-QUINAZOLIN-2-YL)- METHYL-AMINO]PROPYL] TETRAHYDROFURAN- 2-CARBOXAMIDE
SL-7749910
SL-77499-10
SL-77499-10|SL-7749910|Uroxatral®
Urion
UroXatral
Xatral
|
|
5 |
|
Cadexomer iodine |
Experimental |
Phase 4 |
|
94820-09-4 |
|
Synonyms:
|
6 |
|
Anti-Infective Agents |
|
Phase 4 |
|
|
|
7 |
|
Anti-Infective Agents, Local |
|
Phase 4 |
|
|
|
8 |
|
Blood Substitutes |
|
Phase 4 |
|
|
|
9 |
|
Plasma Substitutes |
|
Phase 4 |
|
|
|
10 |
|
Adrenergic alpha-Antagonists |
|
Phase 4 |
|
|
|
11 |
|
Neurotransmitter Agents |
|
Phase 4 |
|
|
|
12 |
|
Adrenergic Antagonists |
|
Phase 4 |
|
|
|
13 |
|
Adrenergic alpha-1 Receptor Antagonists |
|
Phase 4 |
|
|
|
14 |
|
Adrenergic Agents |
|
Phase 4 |
|
|
|
15 |
|
Ethanol |
Approved |
Phase 1, Phase 2 |
|
64-17-5 |
702 |
Synonyms:
[CH2Me(OH)]
[OEtH]
1-Hydroxyethane
ABLYSINOL
Absolute alcohol
Absolute ethanol
Absolute ethyl alcohol
Aethanol
Aethylalkohol
Alcare hand degermer
Alcohol
Alcohol (ethyl)
Alcohol anhydrous
Alcohol denatured
ALCOHOL DETERMINATION--ALCOHOL
Alcohol etilico
Alcohol etílico
Alcohol, absolute
Alcohol, Dehydrated
Alcohol, denatured
ALCOHOL, DILUTED
Alcohol, ethyl
Alcohol, grain
ALCOHOL, RUBBING
Alcohols
Alcool ethylique
Alcool éthylique
Alcool etilico
Algrain
Alkohol
Alkoholu etylowego
Aminoethanol
Anhydrol
Anhydrous alcohol
Anhydrous ethanol
Äthanol
Äthylalkohol
B3324
Beta-Aminoethanol
Beta-Aminoethyl Alcohol
Beta-Ethanolamine
Beta-Hydroxyethylamine
C2H5OH
Caswell No. 426
Colamine
Cologne spirit
Cologne spirits
Dehydrated alcohol
Dehydrated ethanol
Denatured alcohol
Denatured Alcohol Cd-10
Denatured Alcohol Cd-5
Denatured Alcohol Cd-5a
Denatured Alcohol Sd-1
Denatured Alcohol Sd-13a
Denatured Alcohol Sd-17
Denatured Alcohol Sd-23a
Denatured Alcohol Sd-28
Denatured Alcohol Sd-30
Denatured Alcohol Sd-39b
Denatured Alcohol Sd-39c
Denatured Alcohol Sd-3a
Denatured Alcohol Sd-40m
Denatured ethanol
Desinfektol el
Diluted alcohol
Distilled spirits
DRINKING ALCOHOL
E1510
Envision Conditioner Pdd 9020
ETA
Etanol
|
Etanolo
ETHANOL
éthanol
Ethanol 200 proof
Ethanol Absolute
Ethanol Absolute Bp
Ethanol Anhydrous
Ethanol Extra Pure
Ethanol solution
Ethanol, Silent Spirit
Ethicap
Ethyl alc
Ethyl alcohol
Ethyl Alcohol & Water, 10%
Ethyl Alcohol & Water, 20%
Ethyl Alcohol & Water, 30%
Ethyl Alcohol & Water, 40%
Ethyl Alcohol & Water, 5%
Ethyl Alcohol & Water, 50%
Ethyl Alcohol & Water, 60%
Ethyl Alcohol & Water, 70%
Ethyl Alcohol & Water, 80%
Ethyl Alcohol & Water, 95%
Ethyl Alcohol & Water, 96%
Ethyl alcohol anhydrous
Ethyl alcohol in alcoholic beverages
Ethyl alcohol usp
Ethyl Alcohol, Anhydrous
Ethyl Alcohol, Denatured
Ethyl hydrate
Ethyl hydroxide
Ethylol
Ethylolamine
EtOH
FEMA NO. 2419
Fermentation alcohol
Glycinol
Grain alcohol
Hinetoless
HSDB 531
Hydroxyethane
Infinity pure
Jaysol
Jaysol S
Lux
METHYLATED MINERAL
Methylated Spirit Mineralised
Methylcarbinol
Molasses alcohol
NCI-C03134
NSC-85228
PM-6193-200
Potato alcohol
Punctilious ethyl alcohol
Pyro
Reagent Alcohol
Silent spirit
SPIRIGEL
Spirit
Spirits OF wine
Spiritus vini
Spirt
SURG
Synasol
Tecsol
Tecsol C
Thanol
Thiofaco M-50
Undenatured ethanol
USAF EK-1597
VODKA
|
|
16 |
|
Nivolumab |
Approved |
Phase 1, Phase 2 |
|
946414-94-4 |
|
Synonyms:
BMS-936558
BMS-936558|MDX-1106|ONO-4538|Opdivo®
MDX-1106
|
NIVOLUMAB
ONO-4538
OPDIVO
|
|
17 |
|
Coal tar |
Approved |
Phase 1, Phase 2 |
|
8007-45-2 |
|
Synonyms:
|
18 |
|
Ipilimumab |
Approved |
Phase 2 |
|
477202-00-9 |
|
Synonyms:
BMS-734016
Ipilimumab
MDX-010
MDX-010|MDX-101|MDX-CTLA-4|Yervoy®
|
MDX-101
MDX-CTLA-4
MOAB-CTLA-4
YERVOY
|
|
19 |
|
Imatinib Mesylate |
|
Phase 2 |
|
220127-57-1 |
|
Synonyms:
GLEEVEC
GLIVEC
IMATINIB MESILATE
IMATINIB MESYLATE
|
IMATINIB METHANESULFONATE
STI571
STI-571
|
|
20 |
|
Protein Kinase Inhibitors |
|
Phase 2 |
|
|
|
21 |
|
Hormones |
|
Phase 1, Phase 2 |
|
|
|
22 |
|
Androgens |
|
Phase 1, Phase 2 |
|
|
|
23 |
|
Hormone Antagonists |
|
Phase 1, Phase 2 |
|
|
|
24 |
|
Immunoglobulins, Intravenous |
|
Phase 1, Phase 2 |
|
|
|
25 |
|
Immunoglobulins |
|
Phase 1, Phase 2 |
|
|
|
26 |
|
Immunoglobulin G |
|
Phase 1, Phase 2 |
|
|
|
27 |
|
Immune Checkpoint Inhibitors |
|
Phase 1, Phase 2 |
|
|
|
28 |
|
Antibodies, Monoclonal |
|
Phase 1, Phase 2 |
|
|
|
29 |
|
Antibodies |
|
Phase 1, Phase 2 |
|
|
|
30 |
|
Antineoplastic Agents, Immunological |
|
Phase 1, Phase 2 |
|
|
|
31 |
|
Gallium 68 PSMA-11 |
|
Phase 2 |
|
|
91800164 |
Synonyms:
(68)Ga-psma
(68Ga)glu-urea-lys(ahx)-hbed-CC
68 Ga-psma-I and T
68 Ga-psma-I-T
68Ga-psma
|
68Ga-psma-11
GA-68 psma-11
Gallium ga-68 gozetotide
Glu-NH-CO-NH-lys-(ahx)-((68)ga(hbed-CC))
Glu-NH-CO-NH-lys-(ahx)-(68ga(hbed-CC))
|
|
32 |
|
Taxane |
|
Phase 1, Phase 2 |
|
|
108169 |
33 |
|
177Lu-PSMA-617 |
|
Phase 2 |
|
|
|
34 |
|
Hops |
Approved |
|
|
|
|
35 |
|
Finasteride |
Approved |
|
|
98319-26-7 |
57363 |
Synonyms:
(5a,17b)-(1,1-Dimethylethyl)-3-oxo-4-azaandrost-1-ene-17-carboxamide
(5alpha,17beta)-(1,1-Dimethylethyl)-3-oxo-4-azaandrost-1-ene-17-carboxamide
(5Α,17β)-(1,1-dimethylethyl)-3-oxo-4-azaandrost-1-ene-17-carboxamide
AINDEEM
Cahill may roberts brand OF finasteride
Chibro proscar
Chibro-proscar
Eucoprost
Finasterida
FINASTERIDE
Finasteridum
Finastid
Finpecia
Frosst iberica brand OF finasteride
Lipha brand OF finasteride
Merck brand 1 OF finasteride
|
Merck brand 2 OF finasteride
Merck frosst brand 1 OF finasteride
Merck frosst brand 2 OF finasteride
Merck sharp and dhome brand 2 OF finasteride
Merck sharp and dohme brand 1 OF finasteride
MK 906
MK 906|MK-906|MK906|Propecia®|Proscar®
MK906
MK-906
MSD Brand OF finasteride
MSD Chibropharm brand OF finasteride
Propecia
Propeshia
Proscar
Prostide
|
|
36 |
|
Lidocaine |
Approved, Vet_approved |
|
|
137-58-6 |
3676 |
Synonyms:
2-(Diethylamino)-2',6'-acetoxylidide
2-(Diethylamino)-N-(2,6-dimethylphenyl)acetamide
2-2ETN-2MePhAcN
a-Diethylamino-2,6-dimethylacetanilide
ALGRX 3268
ALGRX-3268
ALPHACAINE
alpha-Diethylamino-2,6-dimethylacetanilide
ANESTACON
Astrazeneca brand OF lidocaine
Dalcaine
Dentipatch
Dilocaine
EMBOLEX
IONTOCAINE
Jenapharm brand OF lidocanine hydrochloride
L-Caine
Lidocaina
Lidocaína
LIDOCAINE
Lidocaine carbonate
Lidocaine carbonate (2:1)
Lidocaine hydrocarbonate
Lidocaine hydrochloride
Lidocaine monoacetate
Lidocaine monohydrochloride
|
Lidocaine monohydrochloride, monohydrate
Lidocaine sulfate (1:1)
Lidocainum
LIDOCATON
Lidoderm
LIDOPEN
Lignocaine
LIGNOCAINE HCL
LIGNOSTAB
LMX 4
Novocol brand OF lidocaine hydrochloride
NSC-40030
Octocaine
ORAQIX
Strathmann brand OF lidocaine hydrochloride
VAGISIL
Xylesthesin
Xylocaine
Xylocaine®
Xylocitin
XYLODASE
Xyloneural
XYLOTOX
ZTLIDO
Α-diethylamino-2,6-dimethylacetanilide
|
|
37 |
|
Ceftriaxone |
Approved |
|
|
73384-59-5 |
5479530 |
Synonyms:
(6R,7R)-7-{[(2Z)-2-(2-amino-1,3-thiazol-4-yl)-2-(methoxyimino)acetyl]amino}-3-{[(2-methyl-5,6-dioxo-1,2,5,6-tetrahydro-1,2,4-triazin-3-yl)sulfanyl]methyl}-8-oxo-5-thia-1-azabicyclo[4.2.0]oct-2-ene-2-carboxylate
(6R,7R)-7-{[(2Z)-2-(2-amino-1,3-thiazol-4-yl)-2-(methoxyimino)acetyl]amino}-3-{[(2-methyl-5,6-dioxo-1,2,5,6-tetrahydro-1,2,4-triazin-3-yl)sulfanyl]methyl}-8-oxo-5-thia-1-azabicyclo[4.2.0]oct-2-ene-2-carboxylic acid
(6R,7R)-7-{[(2Z)-2-(2-amino-1,3-thiazol-4-yl)-2-(methoxyimino)acetyl]amino}-3-{[(2-methyl-5,6-dioxo-1,2,5,6-tetrahydro-1,2,4-triazin-3-yl)sulphanyl]methyl}-8-oxo-5-thia-1-azabicyclo[4.2.0]oct-2-ene-2-carboxylate
(6R,7R)-7-{[(2Z)-2-(2-amino-1,3-thiazol-4-yl)-2-(methoxyimino)acetyl]amino}-3-{[(2-methyl-5,6-dioxo-1,2,5,6-tetrahydro-1,2,4-triazin-3-yl)sulphanyl]methyl}-8-oxo-5-thia-1-azabicyclo[4.2.0]oct-2-ene-2-carboxylic acid
Anhydrous ceftriaxone sodium
Benaxona
Biotrakson
Boehringer mannheim brand OF ceftriaxone sodium
C18H18N8O7S3
Cefatriaxone
Cefaxona
Ceftrex
Ceftriaxon
Ceftriaxon curamed
Ceftriaxon hexal
Ceftriaxona
Ceftriaxona [INN-Spanish]
Ceftriaxona andreu
Ceftriaxona LDP torlan
CEFTRIAXONE
Ceftriaxone irex
Ceftriaxone sodium
Ceftriaxone sodium, anhydrous
Ceftriaxone, disodium salt
Ceftriaxone, disodium salt, hemiheptahydrate
Ceftriaxonum
|
Ceftriaxonum [INN-Latin]
Ceftriazone
Columbia brand OF ceftriaxone
CTRX
Curamed brand OF ceftriaxone sodium
FIDATO
Fustery brand OF ceftriaxone sodium
Galen brand OF ceftriaxone sodium
Hexal brand OF ceftriaxone sodium
Hoffman la roche brand OF ceftriaxone sodium
Hoffman-la roche brand OF ceftriaxone sodium
Inibsa brand OF ceftriaxone sodium
Irex brand OF ceftriaxone
Lendacin
Longacef
Longaceph
Pisa brand OF ceftriaxone sodium
Rocefalin
Rocefin
Rocephin
Rocephine
Roche brand OF ceftriaxone sodium
Sodium, ceftriaxone
Syntex brand OF ceftriaxone sodium
Tacex
Terbac
|
|
38 |
|
Anesthetics, Local |
|
|
|
|
|
39 |
|
Estrogens |
|
|
|
|
|
40 |
|
5-alpha Reductase Inhibitors |
|
|
|
|
|
41 |
|
Anesthetics |
|
|
|
|
|
42 |
|
Anti-Bacterial Agents |
|
|
|
|
|
43 |
|
Antibiotics, Antitubercular |
|
|
|
|
|
44 |
|
Radiopharmaceuticals |
|
|
|
|
|
Interventional clinical trials:
(show all 45)
# |
Name |
Status |
NCT ID |
Phase |
Drugs |
1 |
A Prospective Randomized Trial of Povidone-iodine Suppository Before Transrectal Ultrasound Guided Prostate Biopsy |
Unknown status |
NCT02245334 |
Phase 4 |
Povidone-Iodine |
2 |
ALEX-XL: Alfuzosin XL-Lower Urinary Tract Symptoms Efficacy and Sexuality Study |
Completed |
NCT00575913 |
Phase 4 |
Alfuzosin |
3 |
Evaluation of the Safety and Tolerability of Transurethral Alcohol Injection for the Treatment of BPH (Enlarged Prostate) |
Completed |
NCT00037141 |
Phase 1, Phase 2 |
dehydrated alcohol |
4 |
An Open-label, Multicenter, Phase II Study to Evaluate the Ability of Glivec® (Imatinib, Formerly Known as STI571) to Produce a Biochemical Response in Patients With Rising PSA Following Radical Prostatectomy |
Completed |
NCT01316458 |
Phase 2 |
STI571 (Glivec®) |
5 |
Combination of Nivolumab Immunotherapy With Radiation Therapy and Androgen Deprivation Therapy in the Management of Gleason Group 5 Prostate Cancer |
Recruiting |
NCT03543189 |
Phase 1, Phase 2 |
Nivolumab;Androgen Deprivation Therapy |
6 |
An Open-label, Multicentre, Integrated Phase 1 & 2 Study to Evaluate the Safety, Tolerability, Radiation Dosimetry and Anti-tumour Activity of Lutetium (177Lu) rhPSMA-10.1 Injection in Men With Metastatic Castrate-resistant Prostate Cancer |
Recruiting |
NCT05413850 |
Phase 1, Phase 2 |
177Lu-rhPSMA-10.1 injection |
7 |
Phase II Study of Radionuclide 177Lu-PSMA Therapy Versus 177Lu-PSMA in Combination With Ipilimumab and Nivolumab for Men With MetastaticCastration Resistant Prostate Cancer (mCRPC) |
Recruiting |
NCT05150236 |
Phase 2 |
177Lu-PSMA-617;Ipilimumab;Nivolumab |
8 |
High-Resolution, 18F-PSMA PET-MRI for Mapping Prostate Cancer in Patients Considering Focal High-Intensity Focused Ultrasound (HIFU) Therapy or Radical Prostatectomy |
Recruiting |
NCT04461509 |
Phase 2 |
18F-PSMA |
9 |
A Phase 1/2 Open-Label Study to Assess the Safety, Pharmacokinetics, and Anti-Tumor Activity of Oral EPI-506 in Patients With Metastatic Castration-Resistant Prostate Cancer |
Terminated |
NCT02606123 |
Phase 1, Phase 2 |
EPI-506 |
10 |
A Phase II Study of Ixabepilone Prior to Surgery for High-risk Localized Prostate Cancer |
Terminated |
NCT00672009 |
Phase 2 |
Ixabepilone |
11 |
4-aminopyridine Treatment for Nerve Injury From Radical Retro-Pubic Prostatectomy |
Withdrawn |
NCT03658408 |
Phase 2 |
4-aminopyridine;placebo |
12 |
Pilot Study to Evaluate In Vivo Plastic Scintillation Detectors for Real-Time Radiation Dosimetry During Prostate Cancer Radiotherapy |
Completed |
NCT01307852 |
Phase 1 |
|
13 |
A Phase 1 Dose Escalation and Expanded Cohort Study of P-PSMA-101 in Subjects With Metastatic Castration-Resistant Prostate Cancer (mCRPC) and Advanced Salivary Gland Cancers (SGC) |
Active, not recruiting |
NCT04249947 |
Phase 1 |
Rimiducid |
14 |
Ejaculation Preserving Photoselective Vaporization Versus Plasma Kinetic Vaporization Versus Transurethral Resection Of The Prostate For Management Of Benign Prostatic Enlargement: An Objective Evaluation Through a Prospective Randomized Trial |
Unknown status |
NCT03589196 |
|
|
15 |
MR/TRUS Fusion Guided Prostate Biopsy- An Improved Way To Detect And Quantify Prostate Cancer |
Unknown status |
NCT04026763 |
|
|
16 |
Hypnosis Mask: a New Approach to Management of Pain in Medical Imaging |
Unknown status |
NCT03711643 |
|
|
17 |
68Ga PSMA-11 in Patients With Intermediate to High-risk Prostate Cancer Before Prostatectomy or With Biochemical Recurrence of Prostate Cancer. |
Approved for marketing |
NCT04452136 |
|
68GA PSMA-HBED-CC |
18 |
Configuration of a New Prostate Disease Nomogram Predicting Prostate Biopsy Outcome Correlating Clinical Indicators Among Asian Adult Males With Elevated Prostate Specific Antigen (PSA) |
Completed |
NCT01826617 |
|
|
19 |
Intratesticular Hormone Levels in Healthy Young Men |
Completed |
NCT00756561 |
|
|
20 |
The Relationship Between Serum PSA Levels and WBC, Delta Neutrophil Index (DNI) and Other Hematological Parameters |
Completed |
NCT05399940 |
|
|
21 |
Prospective Evaluation of the Intraoperative Use of Translumenal Flexible Endoscopes During Combined Flexible and Laparoscopic Foregut and Urologic Surgery |
Completed |
NCT00484783 |
|
|
22 |
Randomized, Evaluator-blind, Controlled Trial to Evaluate the Efficacy and Safety of Prostatic Arterial Embolization Versus a Sham Procedure for Benign Prostatic Hyperplasia With Severe LUTS Not Adequately Controlled With Alpha-blockers |
Completed |
NCT02074644 |
|
|
23 |
Prostatic Artery Embolization for Obstructive Uropathy Due to Prostate Cancer |
Completed |
NCT03104907 |
|
|
24 |
Prostatic Artery Embolization for Benign Prostatic Obstruction |
Completed |
NCT03099421 |
|
|
25 |
Validation of a Semiquantitative Screening Assay for PSA |
Completed |
NCT00853710 |
|
|
26 |
Sexuality and Management of Benign Prostatic Hyperplasia With Alfuzosin |
Completed |
NCT00941343 |
|
Alfuzosin (XATRAL® - SL770499) |
27 |
A Prospective Randomized Study Whether Low-energy Extracorporeal Shockwave Therapy (LI-ESWT) Can Increase Erectile Function in Patients After Radical Prostatectomy |
Completed |
NCT03192917 |
|
|
28 |
Development of an Evaluation Method of Elderly Condition in Patient Receiving Chemotherapy Treatment . Geriatric Oncology Protocol in Aquitaine Country. |
Completed |
NCT00210249 |
|
|
29 |
5-Alpha Reductase 2 as a Marker of Resistance to 5ARI Therapy |
Recruiting |
NCT04288427 |
|
Finasteride |
30 |
MR/TRUS Fusion Guided Prostate Biopsy - An Improved Way to Detect and Quantify Prostate Cancer |
Recruiting |
NCT04599218 |
|
|
31 |
A Study to Evaluate the Safety and Efficacy of Focal US Guided Cryo-ablation Using DynaCAD / UroNAV Preplanning / Guidance of Locally Confined Low to Intermediate Risk Prostate Cancer |
Recruiting |
NCT04656678 |
|
|
32 |
Culturally Adapted Cognitive Behavioral Stress and Self-Management (C-CBSM) Intervention for Prostate Cancer |
Recruiting |
NCT03344757 |
|
|
33 |
Soractelite(Tm) Transperineal Laser Ablation for Benign Prostatic Hyperplasia With Bladder Outlet Obstruction |
Recruiting |
NCT04760483 |
|
|
34 |
Feasibility and Safety of Transurethral HIFU in Various Prostate Diseases; Particularly Prostate Cancer |
Recruiting |
NCT03350529 |
|
|
35 |
Evaluation of Diagnostic Accuracy of [68Ga]Ga-PSMA-11 PET/CT in Primary Staging of Intermediate and High Risk Prostatic Cancer in Men Newly Diagnosed |
Recruiting |
NCT04462926 |
|
|
36 |
Prospective Cohort Study With Collection of Clinical Data, Serum and Plasma of Patients With Prostate Disease |
Active, not recruiting |
NCT04024475 |
|
|
37 |
MRI for Assessment of Hypoxia-Induced Prostate Cancer Aggressiveness |
Active, not recruiting |
NCT01464216 |
|
|
38 |
Molecular Studies and Clinical Correlations in Human Prostatic Disease |
Active, not recruiting |
NCT00578240 |
|
|
39 |
Evaluation of the in Vivo Biodistribution and Radiation Dosimetry of 68Ga-HTK03149 for Use as a Diagnostic Radiopharmaceutical |
Active, not recruiting |
NCT04831307 |
|
|
40 |
Cryoablation: An Observational Study of Hemi-Gland Cryoablation Outcomes for Prostate Cancer at University of California at Los Angeles (UCLA) |
Enrolling by invitation |
NCT03503643 |
|
|
41 |
Evaluation of a Soft Tissue Biopsy System for Trans-rectal and Trans-perineal Biopsy of the Prostate |
Not yet recruiting |
NCT05470127 |
|
|
42 |
Evaluating the Role of Biparametric MRI and Image-fusion Targeted Biopsies for Detection of Prostate Cancer |
Not yet recruiting |
NCT05574647 |
|
|
43 |
A Questionnaire Study by Elevated Prostate Specific Antigen (PSA): Do Men Where Subsequent Assessment Shows Prostate Cancer, Higher Levels of Neuroticism and Stress Compared to Those Who do Not Get the Diagnosis? |
Terminated |
NCT02031029 |
|
|
44 |
Effect of Laser Settings on Postoperative Voiding Symptoms in Patients Undergoing Holmium Laser Enucleation of the Prostate: A Randomized Prospective Trial |
Withdrawn |
NCT04699552 |
|
|
45 |
ConfirmMDx Assay is Multiparametric MRI (mpMRI) PIRADS Scored Lesions After a Negative MR/US Fusion Biopsy |
Withdrawn |
NCT03597386 |
|
|
Inferred drug relations via
UMLS
71
/
NDF-RT
50
:
|